ST
STOK.US Stoke Therapeutics Inc
- Market cap
- USD 1.73B
- P/E
- -
- P/B
- 4.94x
- ROE
- -70.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is STOK.US undervalued?
Graham numberThe Graham number of Stoke Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Stoke Therapeutics Inc fundamental analysis
No fundamental analysis for Stoke Therapeutics Inc yet.
Stoke Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001),…
Full company profileStoke Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Stoke Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.00M | 12.4M | 8.78M | 36.6M | 184M | 35.7M |
| Gross Profit | -113K | -214K | -450K | -1.93M | -2.23M | 12.4M | 8.78M | 36.6M | 184M | 32.8M |
| Operating Income | -5.55M | -12.8M | -35.7M | -53.0M | -86.1M | -104M | -115M | -101M | -20.6M | -262M |
| EBITDA | -5.44M | -12.6M | -35.2M | -52.2M | -85.1M | -103M | -102M | -86.8M | -5.12M | -246M |
| Net Income | -5.56M | -12.5M | -28.5M | -50.6M | -84.7M | -93.1M | -105M | -89.0M | -6.89M | -247M |
| EPS | -0.24 | -0.53 | -1.59 | -1.51 | -2.31 | -2.39 | -2.38 | -1.65 | -0.12 | -3.61 |
| Balance Sheet | ||||||||||
| Total Assets | 2.44M | 108M | 229M | 298M | 239M | 256M | 228M | 272M | 418M | 407M |
| Total Liabilities | 3.73M | 2.47M | 4.32M | 11.8M | 21.1M | 71.2M | 68.8M | 42.5M | 66.0M | 54.1M |
| Shareholders' Equity | -1.29M | 105M | 224M | 286M | 218M | 185M | 160M | 229M | 352M | 353M |
| Cash & Short-term Investments | 1.80M | 105M | 222M | 287M | 220M | 230M | 201M | 217M | 285M | 319M |
| Total Debt | 3.00M | - | - | 1.07M | 5.04M | 2.36M | 2.06M | 4.77M | 3.01M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.38M | -11.0M | -31.1M | -42.2M | -66.9M | -31.9M | -81.1M | -86.9M | 45.6M | -240M |
| Capital Expenditure | 113K | 935K | 1.64M | 1.05M | 1.20M | 3.96M | 1.62M | 203K | 670K | 6.91M |
| Free Cash Flow | -5.50M | -11.9M | -32.7M | -43.3M | -68.1M | -35.8M | -82.7M | -87.1M | 44.9M | -247M |
| Ratios | ||||||||||
| ROE | - | -11.9% | -12.7% | -17.7% | -38.9% | -50.4% | -65.6% | -38.9% | -2.0% | -70.1% |
| ROA | -227.9% | -11.6% | -12.5% | -17.0% | -35.5% | -36.4% | -45.9% | -32.8% | -1.6% | -60.7% |
| Net Profit Margin | - | - | - | - | -2,823.7% | -750.6% | -1,192.5% | -243.4% | -3.7% | -691.1% |
| Debt to Equity | - | - | - | 0.00x | 0.02x | 0.01x | 0.01x | 0.02x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Stoke Therapeutics Inc dividends
Stoke Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:9 on Jun 6, 2019.
Who owns Stoke Therapeutics Inc
- Insiders 3.62%
- Institutions 96.38%
- Public & others 0.00%
- Shares outstanding 65.4M
- Free float 46.5M
Top funds holding STOK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 2.92M | 4.47% | +59.73% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.94M | 2.97% | +2.80% | Sep 2026 |
| Fidelity Select Biotechnology | 1.48M | 2.27% | +1.33% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.41M | 2.15% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.39M | 2.12% | 0.00% | Oct 2026 |
| Polar Capital Biotech S Inc | 790K | 1.21% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 628K | 0.96% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 603K | 0.92% | +0.14% | Aug 2026 |
| T. Rowe Price New Horizons | 591K | 0.90% | -11.03% | Sep 2026 |
| Fidelity Small Cap Growth | 521K | 0.80% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 517K | 0.79% | -0.38% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 496K | 0.76% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 488K | 0.75% | -2.88% | Apr 2026 |
| BlackRock Health Sciences Opps Inv A | 473K | 0.72% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 418K | 0.64% | -0.57% | Sep 2026 |
| iShares Biotechnology ETF | 417K | 0.64% | -0.19% | Oct 2026 |
| BGF World Healthscience A2 | 385K | 0.59% | 0.00% | Jul 2026 |
| T. Rowe Price Health Sciences | 371K | 0.57% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 342K | 0.52% | +0.23% | Oct 2026 |
| Fidelity Advisor Health Care I | 330K | 0.50% | 0.00% | Sep 2026 |
Top institutions holding STOK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 5.88M | 8.99% | +9.13% | Jun 2026 |
| RTW INVESTMENTS, LLC | 5.62M | 8.60% | 0.00% | Jun 2026 |
| FMR Inc | 5.31M | 8.12% | -1.31% | Jun 2026 |
| Lynx1 Capital Management, LP | 4.04M | 6.17% | -15.23% | Jun 2026 |
| Redmile Group, LLC | 3.95M | 6.03% | -5.24% | Jun 2026 |
| Wellington Management Company LLP | 3.52M | 5.38% | +13.68% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.45M | 5.28% | +0.86% | Jun 2026 |
| Baker Bros Advisors LP | 3.34M | 5.10% | 0.00% | Jun 2026 |
| The Toronto-Dominion Bank | 3.17M | 4.85% | 0.00% | Jun 2026 |
| State Street Corp | 2.85M | 4.36% | +25.29% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.66M | 4.07% | +37.62% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.59M | 3.96% | +9.82% | Jun 2026 |
| Bvf Inc | 2.55M | 3.90% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.42M | 3.69% | +862.54% | Jun 2026 |
| Assenagon Asset Management SA | 2.26M | 3.45% | +148.81% | Jun 2026 |
| Siren, L.L.C. | 2.00M | 3.05% | 0.00% | Jun 2026 |
| Deerfield Management Co | 1.82M | 2.79% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 1.81M | 2.77% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.52M | 2.33% | +15.28% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 924K | 1.41% | -8.83% | Sep 2026 |
Stoke Therapeutics Inc company profile
- Company name
- Stoke Therapeutics Inc
- Ticker
- STOK.US
- Exchange
- USA Stocks
- Listed since
- Jun 19, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 170
- Fiscal year end
- December
- Address
- 45 Wiggins Avenue, Bedford, MA, United States, 01730
- Phone
- 781 430 8200
- Website
- stoketherapeutics.com
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics Inc management
10- Mr. Ian F. Smith A.C.A., C.P.A.CEO & Director · born 1966
- Dr. Adrian R. Krainer Ph.D.Co-Founder & Independent Director · born 1959
- Mr. Thomas Edward LeggettChief Financial Officer · born 1977
- Mr. Jason HoittChief Patient Officer · born 1978
- Ms. Isabel Aznarez Ph.D.Co-Founder & CTO · born 1972
- Dr. Thomas McCauley Ph.D.Chief Scientific Officer · born 1969
- Mr. Jonathan Allan J.D.Corporate Secretary, Compliance Officer & General Counsel · born 1990
- Susan WillsonVice President of Corporate Communications
- Ms. Sara Den BestenChief People Officer
- Dr. Barry S. Ticho FACC, M.D., Ph.D.Chief Medical Officer · born 1960